A phase II study of combination chemotherapy with docetaxel and carboplatin for patients with advanced or metastatic non-small cell lung cancer

Anticancer Research

Volumn 26, Issue 5 B, 2006, Pages 3723-3728

  Kasahara, Kazuo ^a   Kimura, Hideharu ^a   Shibata, Kazuhiko ^b   Araya, Tomoyuki ^a   Sone, Takashi ^a   Oribe, Yoshitaka ^a,e   Furusho, Shiho ^a   Kita, Toshiyuki ^c   Shirasaki, Hiroki ^d   Yoshimi, Yuzo ^f   Ueda, Akihito ^g   Tachibana, Hideki ^a   Shintani, Hiromoto ^h   Mizuguchi, Masayuki ⁱ   Nishi, Kohichi ⁱ   Fujimura, Masaki ^a   Nakao, Shinji ^a  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^b KOUSEIREN TAKAOKA HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KANAZAWA MEDICAL CENTER   (Japan)

^d FUKUI KEN SAISEIKAI HOSPITAL   (Japan)

^e Keijyu Medical Center   (Japan)

^f Kaga Central Hospital   (Japan)

^g Noto General Hospital   (Japan)

^h Komatsu Municipal Hospital   (Japan)

ⁱ ISHIKAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Carboplatin; Combination chemotherapy; Docetaxel; NSCLC

Indexed keywords

AMINOTRANSFERASE; CARBOPLATIN; CREATININE; DOCETAXEL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALLERGIC REACTION; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; EDEMA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TAXOIDS;

EID: 33750743388     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156, 2001.
2. Non-small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899-909, 1995.
3. Rudd RM, Gower NH, James LE, Gregory W, Eisen T, Lee SM, Harper PG and Spiro SG: Phase III randomised comparison of gemicitabine and carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIP) in Non-Small-Cell Lung Cancer (NSCLC). Proc Am Soc Clin Oncol 21: 292a, Abstract #1164, 2002.
4. Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, Sugiura T, Kawahara M, Yokoyama A, Yokota S, Yoneda S, Matsui K, Kudo S, Shibuya M, Isobe T, Segawa Y, Nishiwaki Y, Ohashi Y and Niitani H: Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22: 254-261, 2004.
5. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J and Comis R: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 7: 1602-1613, 1989.
6. Kasahara K, Myo S, Iwasa K, Kimura H, Shirasaki H, Yasuda U, Shibata K, Shintani H, Nishi K, Fujimura M and Nakao S: A phase I study of carboplatin and docetaxel for advanced non-small cell lung cancer using the continual reassessment method. Jpn J Clin Oncol 32: 512-516, 2002.
7. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME and Wiltshaw E: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J CHn Oncol 7: 1748-1756, 1989.
8. Jelliffe RW and Jelliffe SM: Estimation of creatinine clearance from changing serum-creatinine levels. Lancet 2: 710, 1971.
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
10. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10, 1989.
11. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J and Johnson DH: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002.
12. Kubota K, Nishiwaki Y, Ohashi Y, Saijo N, Ohe Y, Tamura T, Negoro S, Ariyoshi Y, Nakawgawa K and Fukuoka M: The Four-Arm Cooperative Study (FACS) for advanced Non-Small Cell Lung Cancer (NSCLC). Proc Am Soc Clin Oncol 22: #7006, 2004.
13. Jahanzeb M, Sarna G, Hirsch R, Radice P, Koletsky A, Martinez M, Kruglyak E, Wolin E, Camacho E, Kronish L and Motl S: Docetaxel and carboplatin as first-line therapy in advanced non-small cell lung carcinoma: a phase II study. Anticancer Res 24: 1239-1242, 2004.
14. Schuette W, Bork I, Wollschlanger B and Schadlich S: Combination chemotherapy with docetaxel and carboplatin for advanced non-small cell lung cancer. Clin Drug Invest 21: 161-168, 2001.
15. Belani CP, Einzig A, Bonomi P, Dobbs T, Capozzoli MJ, Earhart R, Cohen LJ and Luketich JD: Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. Ann Oncol 11: 673-678, 2000.
16. Ramalingam S, Dobbs TW, Einzig AI, Wojtowicz-Praga S, Cascino M, Bonomi P and Belani CP: Carboplatin and docetaxel in advanced non-small-cell lung cancer: results of a multicenter phase II study. Cancer Chemother Pharmacol 53: 439-444, 2004.
17. Millward MJ, Boyer MJ, Lehnert M, Clarke S, Rischin D, Goh BC, Wong J, McNeil E and Bishop JF: Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol 14: 449-454, 2003.
18. Tanigawa Y, Sasaki Y, Otsu T, Fujii H, Kashimura M, Sasaki T, Okumura K and Taguchi T: Population Pharmacokinetics of Docetaxel in Japanese Patients. Proc Am Soc Clin Oncol 75: #1518, 1996.
19. Gandara DR, Ohe Y, Kubota K, Nishiwaki Y, Ariyoshi Y, Saijo N, Williamson S, Lara PN, Crowley J and Fukuoka M: Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A modl for prospective comparison of cooperative group trials. Proc Am Soc Clin Oncol 23: #7007, 2004.
20. Fossela F, Perreira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramleu R, Szczesna A, Fidias P, Millward M and Belani CP: Randomized, multinational, phase II study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group. J Clin Oncol 21: 3016-3021, 2003.